Regeneron Pharmaceuticals Inc (REGN.O) significantly raised its 2012 sales forecast for its key eye drug Eylea, suggesting fast adoption of the recently approved drug, sending its shares to a lifetime high. The company, which has a market capitalization of about $10 billion, now expects Eylea net sales of $250 million to $300 million in the United States in 2012. It had earlier forecast net sales of $140 million to $160 million for the drug, which received U.S. regulatory approval in November to treat a common cause of blindness in the elderly.
